CMF Bone Stimulation as Adjunct to Surgical Treatment of Ankle Fractures
- Conditions
- Bimalleolar Ankle Fractures
- Interventions
- Device: Active Combined Magnetic Field OL1000 Bone Growth StimulatorDevice: Sham Combined Magnetic Field OL1000 Bone Growth Stimulator
- Registration Number
- NCT02688855
- Lead Sponsor
- Encore Medical, L.P.
- Brief Summary
The OL1000 is intended to be used as a non-invasive adjunctive treatment for adult males or females that have sustained a closed, unstable ankle fracture that requires surgical treatment for stabilization. The initiation of the adjunctive treatment is to begin within 11 days of surgical stabilization.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 217
- Subject is diagnosed with an unstable, closed, isolated fracture of the ankle and underwent operative stabilization with plate(s) and/or screws (Weber Ankle Fracture Classification B and C)
- Subject has an open fracture
- Subject has any additional fractures of another bone besides the ankle fracture that is to be treated in the study including the contralateral ankle
- Surgical stabilization was definitively performed with an external fixation system
- Surgical stabilization was performed in such a manner that it will result in a fusion of the ankle joint
- Malreduced Ankle as described by Phillips, et al 1985 JBJS
- Surgical procedure included the use of osteoinductive materials in addition to rigid fixation
- BMI ≥ 40 kg/m2
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Investigational Group Active Combined Magnetic Field OL1000 Bone Growth Stimulator Standard Rigid Fixation + Active OL1000 device Control Group Sham Combined Magnetic Field OL1000 Bone Growth Stimulator Standard Rigid Fixation + Sham OL1000 device
- Primary Outcome Measures
Name Time Method Non-powered, composite safety endpoint consisting of: Joint Position Outcome Radiographic Failure and Repeat, Unplanned Surgery at the Operative Site and Device-Related Serious Adverse Events 6 months & 12 months Change overtime of Olerud and Molander Ankle Score (OMAS) 6 weeks, 8 weeks, 10 weeks and 12 weeks
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (9)
Cedars-Sinai Medical Center
🇺🇸Los Angeles, California, United States
Orthopaedic Associates of South Broward, P.A.
🇺🇸Hollywood, Florida, United States
William Beaumont Hospital
🇺🇸Royal Oak, Michigan, United States
University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
Rutgers Biomedical Health Sciences
🇺🇸Newark, New Jersey, United States
University of Rochester
🇺🇸Rochester, New York, United States
University of Arizona
🇺🇸Tucson, Arizona, United States
University of Virginia
🇺🇸Charlottesville, Virginia, United States
OrlandoHealth
🇺🇸Orlando, Florida, United States